AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22085203 — intervention group
Group type: COMPARATOR
Intervention: Clinical stage and number of positive cores for Gleason score 7 to >7
Number of subjects: 1516
Study 22085203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour volume and serum PSA level per millilitre tumour volume
Number of subjects: 1516
Study 20001392 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 63
Study 20001392 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 63
Study 18548084 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral patterned entrainment intervention (synthetically patterned orocutaneous pulse trains through a pneumatically controlled silicone pacifier)
Number of subjects: 31
Study 18548084 — intervention group
Group type: COMPARATOR
Intervention: Control (non-treated group)
Number of subjects: 31
Study 18548084 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral patterned entrainment intervention
Number of subjects: 31
Study 15935981 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose hGH (16 U/d) for nine days
Number of subjects: 14
Study 15935981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 12796368 — intervention group
Group type: COMPARATOR
Intervention: recombinant human LIF (rhLIF) at doses of 0.25‐16.0 micro g/kg/day or 4.0 micro g/kg three times daily for 7 days
Number of subjects: 74
Study 12796368 — intervention group
Group type: COMPARATOR
Intervention: recombinant human LIF (rhLIF) at doses of 0.25‐8.0 micro g/kg/day once daily for 14 days or 4.0 micro g/kg three times daily for 7 days
Number of subjects: 74
Study 12796368 — intervention group
Group type: COMPARATOR
Intervention: recombinant human LIF (rhLIF) at doses of >/=4.0 micro g/kg/day
Number of subjects: 74
Study 12796368 — intervention group
Group type: COMPARATOR
Intervention: recombinant human LIF (rhLIF) at higher doses
Number of subjects: 74
Study 12796368 — intervention group
Group type: COMPARATOR
Intervention: recombinant human LIF (rhLIF)
Number of subjects: 74
Study 11113984 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 120
Study 9038496 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning (two 3 min periods of crossclamping and 2 min of reperfusion, followed by 10 min sustained ischaemia)
Number of subjects: 0
Study 9038496 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning
Number of subjects: 0
Study 8393398 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg, four times daily)
Number of subjects: 132
Study 8393398 — intervention group
Group type: COMPARATOR
Intervention: Cromolyn sodium (2 mg, four times daily)
Number of subjects: 132
Study 8393398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 3575558 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (mean plasma level: 0.65 mmol/l)
Number of subjects: 20
Study 3575558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29175417 — intervention group
Group type: EXPERIMENTAL
Intervention: TT genotype for the ESR1 (rs2273206) gene
Number of subjects: 212
Study 29175417 — intervention group
Group type: EXPERIMENTAL
Intervention: CC genotype for the ESRRB (rs1676303) gene
Number of subjects: 212
Study 29175417 — intervention group
Group type: EXPERIMENTAL
Intervention: C allele for the ESRRB (rs1676303) gene
Number of subjects: 212
Study 28122787 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (KTZ)
Number of subjects: 0
Study 28122787 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (RIF)
Number of subjects: 0
Study 25973563 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshly reconstituted incobotulinumtoxinA (10 U)
Number of subjects: 21
Study 25973563 — intervention group
Group type: COMPARATOR
Intervention: Room temperature-stored incobotulinumtoxinA (10 U)
Number of subjects: 21
Study 23278618 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% ivermectin lotion
Number of subjects: 78
Study 23278618 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% ivermectin lotion
Number of subjects: 78
Study 23278618 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ivermectin lotion
Number of subjects: 78
Study 23278618 — intervention group
Group type: COMPARATOR
Intervention: Vehicle placebo
Number of subjects: 78
Study 21664627 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial CD133(+) bone marrow stem cell transplant
Number of subjects: 35
Study 21664627 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting alone
Number of subjects: 35
Study 18452785 — intervention group
Group type: EXPERIMENTAL
Intervention: CCM ON therapy for 3 months
Number of subjects: 11
Study 18452785 — intervention group
Group type: COMPARATOR
Intervention: CCM OFF therapy for 3 months
Number of subjects: 11
Study 16706693 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy
Number of subjects: 0
Study 12939429 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral modified cobratoxin
Number of subjects: 8
Study 12939429 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 8
Study 10845438 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol treatment (30 mg kg(‐1) over the first 5 days)
Number of subjects: 102
Study 10845438 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 102
Study 9097338 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation intervention (8-week program)
Number of subjects: 28
Study 9097338 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control group
Number of subjects: 28
Study 8403133 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg orally
Number of subjects: 20
Study 8403133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31023843 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefapixant 100 mg
Number of subjects: 36
Study 31023843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 28902534 — intervention group
Group type: EXPERIMENTAL
Intervention: Motesanib plus paclitaxel and carboplatin (P/C)
Number of subjects: 401
Study 28902534 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus paclitaxel and carboplatin (P/C)
Number of subjects: 401
Study 28902534 — intervention group
Group type: EXPERIMENTAL
Intervention: Motesanib plus P/C
Number of subjects: 401
Study 28902534 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus P/C
Number of subjects: 401
Study 25661190 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinupret Forte
Number of subjects: 60
Study 25661190 — intervention group
Group type: COMPARATOR
Intervention: Intranasal fluticasone furoate
Number of subjects: 60
Study 24395447 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 20 mg daily for 2 years
Number of subjects: 129
Study 24395447 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (A) 40 mg/m2 and Cyclophosphamide (C) 500 mg/m2 plus Tamoxifen (ACT)
Number of subjects: 129
Study 24395447 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (A) and Cyclophosphamide (C) plus Tamoxifen (ACT)
Number of subjects: 129
Study 22895994 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-intensity RT
Number of subjects: 54
Study 22895994 — intervention group
Group type: COMPARATOR
Intervention: Lower-intensity RT
Number of subjects: 54
Study 22895994 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 54
Study 20109118 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic secondary prevention educational intervention
Number of subjects: 304
Study 20109118 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 304
Study 17100962 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoclip
Number of subjects: 100
Study 17100962 — intervention group
Group type: COMPARATOR
Intervention: Triclip
Number of subjects: 100
Study 15704611 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression analyses
Number of subjects: 0
Study 12013158 — intervention group
Group type: COMPARATOR
Intervention: Laser vaporisation
Number of subjects: 289
Study 12013158 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop diathermy excision
Number of subjects: 289
Study 9449273 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-benflumetol
Number of subjects: 617
Study 9449273 — intervention group
Group type: COMPARATOR
Intervention: artesunate-mefloquine
Number of subjects: 617
Study 11990094 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion at 18 degrees C
Number of subjects: 24
Study 11990094 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion at 26 degrees C
Number of subjects: 24
Study 11990094 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion at 22 degrees C
Number of subjects: 24
Study 11990094 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion (all temperatures)
Number of subjects: 24
Study 2172393 — intervention group
Group type: EXPERIMENTAL
Intervention: Oka/Merck varicella vaccine (lot C-K472) with 950 pfu and relative antigen content of 1.0
Number of subjects: 0
Study 2172393 — intervention group
Group type: EXPERIMENTAL
Intervention: Oka/Merck varicella vaccine with 1140 pfu/1.7 relative antigen or 1145 pfu/1.6 relative antigen
Number of subjects: 0
Study 2172393 — intervention group
Group type: COMPARATOR
Intervention: Control group (Oka/Merck varicella vaccine with 950 pfu/1.0 relative antigen content)
Number of subjects: 0
Study 367864 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 367864 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 367864 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate
Number of subjects: 0
Study 367864 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study 367864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30932775 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein complex supplementation (10 mg lutein, 500 mg ascorbic acid, 364 mg tocopherols, 2.5 mg carnosic acid, 2 mg zeaxanthin, 2 mg copper)
Number of subjects: 16
Study 30932775 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein complex supplementation
Number of subjects: 16
Study 30203770 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 0
Study 30203770 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 27547421 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg once daily
Number of subjects: 78
Study 27547421 — intervention group
Group type: COMPARATOR
Intervention: Voglibose 0.2 mg three times a day
Number of subjects: 78
Study 27547421 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 78
Study 24418801 — intervention group
Group type: EXPERIMENTAL
Intervention: Active low-level laser therapy (LLLT) applied at five acupuncture points on the affected knee during nine sessions.
Number of subjects: 49
Study 24418801 — intervention group
Group type: COMPARATOR
Intervention: Placebo low-level laser therapy (LLLT) applied at five acupuncture points on the affected knee during nine sessions.
Number of subjects: 49
Study 22079773 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg XR‐NTX
Number of subjects: 27
Study 22079773 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg XR‐NTX
Number of subjects: 27
Study 22079773 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg XR‐NTX
Number of subjects: 27
Study 19330703 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 hourly feeds
Number of subjects: 92
Study 19330703 — intervention group
Group type: COMPARATOR
Intervention: 2 hourly feeds
Number of subjects: 92
Study 17595249 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg/d
Number of subjects: 56
Study 17595249 — intervention group
Group type: COMPARATOR
Intervention: diet alone
Number of subjects: 56
Study 15346755 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmandibular implant
Number of subjects: 60
Study 15346755 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation of the mandible with an autologous bone graft followed by placement of 4 endosseous implants
Number of subjects: 60
Study 15346755 — intervention group
Group type: COMPARATOR
Intervention: Placement of 4 endosseous implants only
Number of subjects: 60
Study 11224756 — intervention group
Group type: COMPARATOR
Intervention: Iomeprol
Number of subjects: 3200
Study 11224756 — intervention group
Group type: EXPERIMENTAL
Intervention: Iomeprol-containing liposomal formulations
Number of subjects: 3200
Study 9586887 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine plus interferon (IFN)
Number of subjects: 271
Study 9586887 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine without interferon (IFN)
Number of subjects: 271
Study 9586887 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine plus tamoxifen (TMX)
Number of subjects: 271
Study 9586887 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine without tamoxifen (TMX)
Number of subjects: 271
Study 9586887 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 271
Study 9586887 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatments containing interferon (IFN)
Number of subjects: 271
Study 9586887 — intervention group
Group type: COMPARATOR
Intervention: Treatments without interferon (IFN)
Number of subjects: 271
Study 7733596 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally pre‐peritoneal video‐surgery
Number of subjects: 181
Study 7733596 — intervention group
Group type: COMPARATOR
Intervention: Classic Shouldice herniography
Number of subjects: 181
Study 2719175 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine chloride control (10 mg/ml)
Number of subjects: 484
Study 2719175 — intervention group
Group type: COMPARATOR
Intervention: Buffered glycerol-saline diluent control
Number of subjects: 484
Study 31481307 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprotected LMS
Number of subjects: 469
Study 31481307 — intervention group
Group type: EXPERIMENTAL
Intervention: STEMI PCI in unprotected LMS
Number of subjects: 469
Study 31481307 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictors of in-hospital death and major adverse cardiovascular events
Number of subjects: 469
Study 30536639 — intervention group
Group type: EXPERIMENTAL
Intervention: Bounding Exercise Program (BEP)
Number of subjects: 400
Study 30536639 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular training program)
Number of subjects: 400
Study 30536639 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BEP and Control)
Number of subjects: 400
Study 27548732 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 75
Study 27548732 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet (HCD)
Number of subjects: 75
Study 24746974 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupin protein (LP) 25 g/d
Number of subjects: 72
Study 24746974 — intervention group
Group type: COMPARATOR
Intervention: Milk protein plus arginine (MPA)
Number of subjects: 72
Study 24746974 — intervention group
Group type: COMPARATOR
Intervention: Milk protein (MP)
Number of subjects: 72
Study 24798861 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) training for 8 weeks
Number of subjects: 110
Study 24798861 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 110
Study 23054692 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg empagliflozin q.d. for 5 days
Number of subjects: 16
Study 23054692 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of 50 mg empagliflozin q.d. and 100 mg sitagliptin q.d. over 5 days
Number of subjects: 16
Study 23054692 — intervention group
Group type: COMPARATOR
Intervention: 100 mg sitagliptin q.d. for 5 days
Number of subjects: 16
Study 19541737 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress (via mental arithmetic)
Number of subjects: 16
Study 19541737 — intervention group
Group type: COMPARATOR
Intervention: HDT
Number of subjects: 16
Study 19541737 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined mental stress and HDT
Number of subjects: 16
Study 17448065 — intervention group
Group type: EXPERIMENTAL
Intervention: Levitan FPS scope (LFPS)
Number of subjects: 34
Study 17448065 — intervention group
Group type: COMPARATOR
Intervention: Single-use bougie
Number of subjects: 34
Study 15601268 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 40 microg with a 2‐min lockout
Number of subjects: 39
Study 15601268 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 15 mg with a 10‐min lockout
Number of subjects: 39
Study 15601268 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 39
Study 15601268 — intervention group
Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 39
Study 12584829 — intervention group
Group type: EXPERIMENTAL
Intervention: Yishenkang granule (YSKG)
Number of subjects: 120
Study 12584829 — intervention group
Group type: COMPARATOR
Intervention: Sanjin tablet
Number of subjects: 120
Study 12584829 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 120
Study 10506687 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular spray administration
Number of subjects: 126
Study 10506687 — intervention group
Group type: COMPARATOR
Intervention: Ocular drops administration
Number of subjects: 126
Study 7503039 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) with a 30 mW gallium-arsenide-aluminium (830 nm) diode laser probe for 15, 30, and 60 seconds.
Number of subjects: 39
Study 7503039 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 30 seconds.
Number of subjects: 39
Study 2020093 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 4 mg i.m. (Group M)
Number of subjects: 28
Study 2020093 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyzine 50 mg i.m. (Group H)
Number of subjects: 28
Study 2020093 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 2 mg and pentazocine 6 mg for intraoperative sedation (both groups)
Number of subjects: 28
Study 2020093 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and pentazocine maintenance doses (both groups)
Number of subjects: 28
Study 2020093 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (Group M)
Number of subjects: 28
Study 2020093 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyzine (Group H)
Number of subjects: 28
Study 2020093 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 6121709 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (1 microgram kg‐1h‐1)
Number of subjects: 5
Study 6121709 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (2 microgram kg‐1h‐1)
Number of subjects: 5
Study 6121709 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin alone
Number of subjects: 5
Study 6121709 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin with prior indomethacin administration
Number of subjects: 5
Study 29727331 — intervention group
Group type: EXPERIMENTAL
Intervention: ALPPS (Associating Liver Partition and Portal vein ligation for Staged hepatectomy)
Number of subjects: 0
Study 29727331 — intervention group
Group type: EXPERIMENTAL
Intervention: ALPPS
Number of subjects: 0
Study 29727331 — intervention group
Group type: COMPARATOR
Intervention: Conventional 2-stage hepatectomy including portal vein embolization
Number of subjects: 0
Study 27544017 — intervention group
Group type: EXPERIMENTAL
Intervention: we DECide
Number of subjects: 0
Study 27544017 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 25791145 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (30‐120 mg daily)
Number of subjects: 272
Study 25791145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 23397566 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic-impregnated catheters (Bactiseal(®))
Number of subjects: 40
Study 23397566 — intervention group
Group type: COMPARATOR
Intervention: Silver-bearing catheters (VentriGuard(®))
Number of subjects: 40
Study 23397566 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study 21808398 — intervention group
Group type: EXPERIMENTAL
Intervention: Video laryngoscopy (group B)
Number of subjects: 30
Study 21808398 — intervention group
Group type: COMPARATOR
Intervention: Conventional laryngoscopy (group A)
Number of subjects: 30
Study 21808398 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 30
Study 19912626 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 246
Study 19912626 — intervention group
Group type: EXPERIMENTAL
Intervention: BI
Number of subjects: 246
Study 17159373 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (HBO) - Group A: 2.2 bar for 60 min bottom time
Number of subjects: 360
Study 17159373 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (HBO) - Group B: 2.5 bar for 60 min bottom time
Number of subjects: 360
Study 17159373 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with positive expectation of HBO effects
Number of subjects: 360
Study 17159373 — intervention group
Group type: COMPARATOR
Intervention: Patients with indifferent expectation of HBO effects
Number of subjects: 360
Study 17159373 — intervention group
Group type: COMPARATOR
Intervention: Patients with negative expectation of HBO effects
Number of subjects: 360
Study 15602194 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 live attenuated human rotavirus vaccine
Number of subjects: 405
Study 15602194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study 11529281 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab every 2 or 4 weeks subcutaneously for 7 months
Number of subjects: 546
Study 11529281 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab during the steroid-reduction phase
Number of subjects: 546
Study 11529281 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 546
Study 9753250 — intervention group
Group type: EXPERIMENTAL
Intervention: rebamipide 100 mg thrice daily for eight weeks
Number of subjects: 102
Study 9753250 — intervention group
Group type: COMPARATOR
Intervention: teprenone 50 mg thrice daily for eight weeks
Number of subjects: 102